Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Issue 31 (30th June 2016)

• Record Type: Journal Article
• Authors: Héquet, Delphine; Pascual, Manuel; Lartey, Sarah; Pathirana, Rishi D.; Bredholt, Geir; Hoschler, Katja; Hullin, Roger; Meylan, Pascal; Cox, Rebecca J.; Manuel, Oriol
• Is Part Of: Vaccine. Volume 34:Issue 31(2016)
• Page Start: 3576
• Page End: 3583
• Publication Date: 2016-06-30
• Subjects: Viral infection -- Biological agents -- Immunogenicity -- Induction -- Prevention; ATG antithymocyte globulins -- SOT solid organ transplant -- HI hemagglutination inhibition -- MBC memory B-cell -- ICS intracellular cytokine staining -- MPA mycophenolic acid -- SFC spot-forming cells -- IL-2 interleukin-2 -- IFN-γ interferon-γ -- TNF-α tumor necrosis factor α; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.05.021
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: We analyzed the impact of the anti-T-cell agents basiliximab and antithymocyte globulins (ATG) on antibody and cell-mediated immune responses after influenza vaccination in solid-organ transplant recipients. Methods: 71 kidney and heart transplant recipients (basiliximab [ n = 43] and ATG [ n = 28]) received the trivalent influenza vaccine. Antibody responses were measured at baseline and 6 weeks post-vaccination by hemagglutination inhibition assay; T-cell responses were measured by IFN-γ ELISpot assays and intracellular cytokine staining (ICS); and influenza-specific memory B-cell (MBC) responses were evaluated using ELISpot. Results: Median time of vaccination from transplantation was 29 months (IQR 8–73). Post-vaccination seroconversion rates were 26.8% for H1N1, 34.1% for H3N2 and 4.9% for influenza B in the basiliximab group and 35.7% for H1N1, 42.9% for H3N2 and 14.3% for influenza B in the ATG group ( p = 0.44, p = 0.61, and p = 0.21, respectively). The number of influenza-specific IFN-γ-producing cells increased significantly after vaccination (from 35 to 67.5 SFC/10 6 PBMC, p = 0.0007), but no differences between treatment groups were observed ( p = 0.88). Median number of IgG-MBC did not increase after vaccination (H1N1, p = 0.94; H3N2 p = 0.34; B, p = 0.79), irrespective of the type of anti-T-cell therapy. Conclusions: After influenza vaccination, a significant increase in antibody and T-cell immune responses but not in MBC responses was observed in transplant recipients. Immune responses were not significantly different between groups that received basiliximab or ATG.